|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.300 USD | +3.60% |
|
+3.60% | +27.78% |
| 05-13 | Protalix BioTherapeutics, Inc., Q1 2026 Earnings Call, May 13, 2026 | |
| 05-13 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | - | 11 | +378.26% | 2 | |||||
| 1,222.62 | +1.2% | 29 | ||||||
| 257.5 | +1.12% | 22 | ||||||
| 254.38 | +0.41% | 29 | ||||||
| 358.83 | +6.8% | 18 | ||||||
| 220.67 | +16.62% | 21 | ||||||
| 154.66 | -1.01% | 21 | ||||||
| 314.62 | -1.05% | 24 | ||||||
| 352.77 | -1.55% | 30 | ||||||
| 157.57 | +23.22% | 28 | ||||||
| 29.15 | +20.01% | 27 | ||||||
| 548.69 | +11.67% | 29 | ||||||
| 63.08 | +9.67% | 25 | ||||||
| 20.87 | +5.24% | 19 | ||||||
| 96.7 | +28.82% | 23 | ||||||
| 9,973.33 | +34.16% | 15 | ||||||
| 51.64 | +9.87% | 18 | ||||||
| 6,086.87 | +19.66% | 15 | ||||||
| 81.14 | +66.71% | 16 | ||||||
| Average | 1,066.11 | +33.15% | 22 | ||||||
| Weighted average by Cap. | 707.47 | +6.40% | 25 |
- Stock Market
- Stocks
- PLX Stock
- Sector Protalix BioTherapeutics, Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
